Search in:

Cancer Biology & Therapy Volume 23, 2022 - Issue 1

Submit an article Journal homepage

Open access

5,128

Views

CrossRef citations to date

Altmetric

Research Article

Feasibility and safety of targeting mitochondria for cancer therapy – preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor

Umar Hayata Pharmaceutical Advisors, LLC, Princeton, USAView further author information

Gary T. Elliottb Galenic Strategies Inc, WindsorView further author information

Anthony J. Olszanskic Phase 1 Developmental Therapeutics Program, Department of Hematology/Oncology Fox Chase Cancer Center, PhiladelphiaView further author information

Dario C. Altierid Immunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, USACorrespondence[email protected]
View further author information

Pages 117-126 | Received 22 Oct 2021, Accepted 10 Jan 2022, Published online: 06 Feb 2022

Cite this article
https://doi.org/10.1080/15384047.2022.2029132
CrossMark

Full Article
Figures & data
References
Supplemental
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF View EPUB EPUB

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (8)

Jaka Dernovšek & Tihomir Tomašič. (2023) Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities. Pharmacology & Therapeutics 245, pages 108396.
Crossref

Martina Raudenská, Kateřina Petrláková, Tamara Juriňáková, Jindřiška Leischner Fialová, Michaela Fojtů, Milan Jakubek, Daniel Rösel, Jan Brábek & Michal Masařík. (2023) Engine shutdown: migrastatic strategies and prevention of metastases. Trends in Cancer 9:4, pages 293-308.
Crossref

Liufeng Zhang, Yuancheng Wei, Shengtao Yuan & Li Sun. (2023) Targeting Mitochondrial Metabolic Reprogramming as a Potential Approach for Cancer Therapy. International Journal of Molecular Sciences 24:5, pages 4954.
Crossref

Soosung Kang & Byoung Heon Kang. (2022) Structure, Function, and Inhibitors of the Mitochondrial Chaperone TRAP1. Journal of Medicinal Chemistry 65:24, pages 16155-16172.
Crossref

Mina Ardestani, Zahra Khorsandi, Fariba Keshavarzipour, Siavash Iravani, Hojjat Sadeghi-Aliabadi & Rajender S. Varma. (2022) Heterocyclic Compounds as Hsp90 Inhibitors: A Perspective on Anticancer Applications. Pharmaceutics 14:10, pages 2220.
Crossref

Jian Zhang, Houde Li, Yu Liu, Kejia Zhao, Shiyou Wei, Eric T. Sugarman, Lunxu Liu & Gao Zhang. (2022) Targeting HSP90 as a Novel Therapy for Cancer: Mechanistic Insights and Translational Relevance. Cells 11:18, pages 2778.
Crossref

Sujae Yang, Nam Gu Yoon, Min-A Park, Jisu Yun, Jin Young Im, Byoung Heon Kang & Soosung Kang. (2022) Triphenylphosphonium conjugation to a TRAP1 inhibitor, 2-amino-6-chloro-7,9-dihydro-8H-purin-8-one increases antiproliferative activity. Bioorganic Chemistry 126, pages 105856.
Crossref

Shiyou WeiDelong Yin, Shengnan YuXiang Lin, Milan R. Savani, Kuang DuYin KuDi WuShasha LiHao LiuMeng TianYaohui ChenMichelle BowieSeethalakshmi HariharanMatthew Waitkus, Stephen T. KeirEric T. SugarmanRebecca A. DeekMarilyne LabrieMustafa Khasraw, Yiling LuGordon B. Mills, Meenhard HerlynKongming WuLunxu Liu, Zhi Wei, Keith T. FlahertyKalil Abdullah, Gao Zhang & David M. Ashley. (2022) Antitumor Activity of a Mitochondrial-Targeted HSP90 Inhibitor in Gliomas. Clinical Cancer Research 28:10, pages 2180-2195.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Feasibility and safety of targeting mitochondria for cancer therapy – preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor

Articles from other publishers (8)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Feasibility and safety of targeting mitochondria for cancer therapy – preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor

Citations (8)

Articles from other publishers (8)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date